期刊文献+
共找到23篇文章
< 1 2 >
每页显示 20 50 100
Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial 被引量:8
1
作者 Zhang Yaojun Chen Fang +21 位作者 Takashi Muramatsu Xu Bo Li Zhanquan Ge Junbo He Qing Yang Zhijian Li Shumei Wang Lefeng Wang Haichang He Ben Li Kang Qi Guoxian Li Tianchang Zeng Hesong Peng Jianjun Jiang Tieming Zeng Qiutang Zhu Jianhua Fu Guosheng Christos V. Bourantas Patrick W. Serruys Huo Yong 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第11期2153-2158,共6页
Background First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST),mainly due to delayed healing and re-endothelization by the durable polymer coating.This st... Background First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST),mainly due to delayed healing and re-endothelization by the durable polymer coating.This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.Methods The Nano trial is the first randomized trial designed to compare the safety and efficacy of the Nano polymer-free SES and Partner durable-polymer SES (Lepu Medical Technology,Beijing,China) in the treatment of patients with de novo native coronary lesions.The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up.The secondary endpoint was major adverse cardiac events (MACE),a composite of cardiac death,myocardial infarction or target lesion revascularization.Results A total of 291 patients (Nano group:n=143,Partner group:n=148) were enrolled in this trial from 19 Chinese centers.The Nano polymer-free SES was non-inferior to the Partner durable-polymer DES at the primary endpoint of 9 months (P 〈0.001).The 9-month in-segment LLL of the polymer-free Nano SES was comparable to the Partner SES (0.34±0.42) mm vs.(0.30±0.48) mm,P=0.21).The incidence of MACE in the Nano group were 7.6% compared to the Partner group of 5.9% (P=0.75) at 2 years follow-up.The frequency of cardiac death and stent thrombosis was low for both Nano and Partner SES (0.8% vs.0.7%,0.8% vs.1.5%,both P=1.00).Conclusions In this multicenter randomized Nano trial,the Nano polymer-free SES showed similar safety and efficacy compared with the Partner SES in the treatment of patients with de novo coronary artery lesions.Trials in patients with complex lesions and longer term follow-up are necessary to confirm the clinical performance of this novel Nano polymer-free SES. 展开更多
关键词 Nano stent polymer-free sirolimus-eluting stent clinical outcomes late lumen loss
原文传递
Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry 被引量:3
2
作者 Zhang Rui-yan Zhang Qi +26 位作者 Zhu Jin-zhou Chen Liang-long Zhang Chen-yun Zhou Xu-chen Yuan Yong Zhong Zhi-xiong Li Lang Qiu Jian Wang Wei Chen Xi-ming Yang Zhi-jian Yan Jin-chuan Chen Shao-liang Hou Yu-qing Wu Yan-qing Luo Hai-ming Qiu Jian-ping Zhu Li Wang Yan Fu Guo-sheng Wang Jian-an Ma Kang-hua Yin Yue-hui Zhang Dai-fu Hu Xue-song Zhu Guo-ying Shen Wei-feng 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第21期3521-3526,共6页
Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention (PCI). The SERY-1 registry ... Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention (PCI). The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events (MACE) and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 (98.7%) patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients (0.78%) had cardiac death, 6 (0.58%) suffered non-fatal myocardial infarction, and 46 (4.46%) underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 (0.97%) patients, and the rate of Academic Research Consortium (ARC) definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation. 展开更多
关键词 polymer-free microporous stent paclitaxel-eluting stent stent thrombosis
原文传递
OCT对无载体纳米药物洗脱支架抑制再狭窄和促进内皮化的动物观察研究 被引量:4
3
作者 刘云升 贺兆发 《贵州医药》 CAS 2014年第6期502-505,共4页
目的评价新型无聚合物涂层雷帕霉素药物洗脱支架在抑制内膜增生、降低炎性反应等方面的安全性和有效性。方法随机选择猪冠状动脉前降支、右冠状动脉或回旋支置入金属裸支架、聚合物载体雷帕霉素洗脱支架(Partner支架)和无聚合物载体雷... 目的评价新型无聚合物涂层雷帕霉素药物洗脱支架在抑制内膜增生、降低炎性反应等方面的安全性和有效性。方法随机选择猪冠状动脉前降支、右冠状动脉或回旋支置入金属裸支架、聚合物载体雷帕霉素洗脱支架(Partner支架)和无聚合物载体雷帕霉素洗脱支架。置入后1个月和3个月行冠脉造影,光学相干断层成像和定量冠脉狭窄分析,测量新生内膜面积、面积狭窄百分比、新生内膜覆盖率等,而后处死动物,进行组织形态学检查和病理积分分析。结果置入后1个月光学相干断层成像、定量冠脉狭窄分析以及组织形态学分析提示,相比金属裸支架、Partner药物洗脱支架和无聚合物载体雷帕霉素洗脱支架明显减少新生内膜面积及管腔丢失。术后3个月,相比金属裸支架和Partner药物洗脱支架,无聚合物载体雷帕霉素洗脱支架明显减少新生内膜面积、管腔丢失。随访期间,BMS组和PFSES组炎症反应及损伤积分之间差异无显著性,但术后3个月PSES组的炎症积分显著升高。结论无聚合物载体雷帕霉素洗脱支架在小型猪模型中,炎性反应程度更轻,无支架内血栓形成,可以有效抑制新生内膜增殖,表现出良好的组织相容性。 展开更多
关键词 无聚合物载体 Partner药物洗脱支架 小型猪冠脉模型
下载PDF
Comparison the long-term clinical outcomes of Nano polymer-free sirolimus-eluting stent versus Endeavor durable polymer zotarolimus-eluting stent in patients with acute coronary syndrome 被引量:1
4
作者 文明洪 刘松 +1 位作者 纪阳 韩兆帅 《South China Journal of Cardiology》 CAS 2016年第3期139-146,共8页
Background Durable polymer drug eluting stent (DES) is confronted with many issues, especially the inci- dence of late stent thrombosis (ST) which is mainly due to delayed healing and re-endothelization by the dur... Background Durable polymer drug eluting stent (DES) is confronted with many issues, especially the inci- dence of late stent thrombosis (ST) which is mainly due to delayed healing and re-endothelization by the durable polymer coating. Newer polymer-free DES might have a reduction in late stent thrombosis. Therefore, the aim of this study was to evaluate the efficacy and safety of two different drug eluting stents in patients with acute coro- nary syndromes (ACS) by one year follow-up. Methods This study assessed the results of the Nano polymer- free SES (Lepu Medical Technology, Beijing, China) and Endeavor durable-polymer ZES (Medtronic, Minneapo- lis, MN, USA) in ACS patients by clinical follow-up and coronary angiography analysis. The primary endpoint was the onset of any major adverse cardiac events (MACE) such as cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR). The secondary endpoints were target lesion revascularization (TLR) and stent thrombosis (ST) at the end of one year follow-up. Results Between April 2014 and June 2015, a total of 513 consecutive patients were enrolled in this trial. There were 259 patients enrolled in Nano group and 253 pa- tients in Endeavor group. Mean age was 62.8 +10.3 years old (range: 28 to 87 years of age), and 65.3% of pa- tients were male. Compared Nano-SES to Endeavor-ZES, the incidence of MACE was 5.4% vs. 7.1%. The hazard ratio (HR) was 1.32 with 95% confidence interval (CI) as 0.64-2.72 (P = 0.45). Secondary end points showed TLR (1.9% vs. 3.2%; HR, 1.42; 95% CI, 0.45-4.55; P = 0.55) and ST (0.4% vs. 0.8%; HR, 2.03; 95% CI, 0.18- 5.37; P = 0.99), in the one-year period of follow-up. Conclusion Within one-year, the Nano polymer-free SES has similar safety and efficacy compared with the Endeavor durable-polymer ZES in the treatment of patients with ACS. 展开更多
关键词 acute coronary syndromes Nano polymer-free drug-eluting stent cardiac events
原文传递
Triboelectricity-assisted transfer of graphene for flexible optoelectronic applications 被引量:1
5
作者 Shuo Liu Qingliang Liao +4 位作者 Shengnan Lu Xiaohui Zhang Zheng Zhang Guangjie Zhang Yue Zhang 《Nano Research》 SCIE EI CAS CSCD 2016年第4期899-907,共9页
In this work, we developed a novel triboelectricity-assisted polymer-free method for the transfer of large-area chemical vapor deposited graphene films. With the assistance of electrostatic forces from friction-genera... In this work, we developed a novel triboelectricity-assisted polymer-free method for the transfer of large-area chemical vapor deposited graphene films. With the assistance of electrostatic forces from friction-generated charges, graphene sheets were successfully transferred from copper foils to flexible polymer substrates. Characterization results confirmed the presence of high quality graphene with less defects and contaminations, compared to graphene transferred by conventional poly(methyl rnethacrylate)-mediated processes. In addition, the graphene samples possessed outstanding electrical transport capabilities and mechanical stability, when studied as electron transfer matrixes in graphene/ZnO hybrid flexible photodetectors. Our results showed a broad application potential for this transfer method in future flexible electronics and optoelectronics. 展开更多
关键词 graphene transfer triboelectricity-assisted polymer-free flexible photodetector
原文传递
程增兵 被引量:2
6
作者 董何彦 马宗民 程增兵 《辽宁师范大学学报(自然科学版)》 CAS 2012年第1期93-97,共5页
传统非降解聚合物药物支架虽可显著降低再狭窄率,但带来了晚期和极晚期支架血栓的风险.针对传统非降解聚合物支架存在的安全隐患,提出一种新型的载药技术:无聚合物微盲孔载药支架技术,认为可能会解决非降解聚合物药物支架存在的问... 传统非降解聚合物药物支架虽可显著降低再狭窄率,但带来了晚期和极晚期支架血栓的风险.针对传统非降解聚合物支架存在的安全隐患,提出一种新型的载药技术:无聚合物微盲孔载药支架技术,认为可能会解决非降解聚合物药物支架存在的问题.新型的无聚合物微盲孔载药技术采用化学方法处理生成微盲孔,微盲孔即为药仓,从而实现直接载药并通过微盲孔的物理性状实现药物缓释,新型无聚合物微盲孔载药支架研究成果现已开发产品,并已规模上市. 展开更多
关键词 无聚合物 药物支架 微盲孔
下载PDF
Efficacy and safety of a novel nano-porous polymer-free sirolimus- eluting stent in pigs
7
作者 CHEN Ming ZHENG Bo WU Zheng PENG Hong-yu WANG Xin-gang ZHANG bin HUO Yong 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第24期4731-4735,共5页
Background Drug-eluting stents represent a major advance in interventional cardiology. However, the current drug- eluting stents have significant limitations. One of the major problems is very late stent thrombosis, w... Background Drug-eluting stents represent a major advance in interventional cardiology. However, the current drug- eluting stents have significant limitations. One of the major problems is very late stent thrombosis, which is likely caused by inflammation and a hypersensitivity reaction related to a polymer on the stent. A polymer-free sirolimus-eluting stent with a unique nano-porous surface has been developed. This study aimed to evaluate this novel polymer-free sirolimus- eluting stent for its efficacy and safety in a pig model. Methods Stents were directly coated with sirolimus (a drug concentration of 2.2 μg/mm2 on the stent surface). The polymer-free sirolimus-eluting stents (PFSES) were compared to standard polymer-coated sirolimus-eluting stents (PCSES) and bare-metal stents (BMS) in 18 pigs. Results At one month the degree of neointimal hyperplasia was similar between the two sirolimus-eluting stent groups and was significantly less compared to BMS ((1.93±0.51) mm2, (1.57±0.69) mm2 vs. (4.45±1.05) mm2, P 〈0.05)At three months, PFSES maintained the low level of neointima ((2.41±0.99) mm2 vs. (4.32±1.16) mm2, P 〈0.05), whereas PCSES had developed significant neointimal proliferation similar to BMS. The inflammation level was significantly higher in PCSES when compared with BMS three months post-implantation (2.50±0.55 vs. 0.83±0.75, P 〈0.05) whereas PFSES showed a low level of inflammation comparable to PCSES (1.33±0.52 vs. 2.50±0.55, P 〈0.05). Conclusion The PFSES is effective and safe. and appears to be suoerior to standard PCSEs. 展开更多
关键词 nano-porous neointimal hyperplasia polymer-free SIROLIMUS THROMBOSIS
原文传递
A novel polymer-free dual-drug eluting stent with nanotechonology
8
作者 俞梦越 张海华 +7 位作者 徐波 吴永健 颜红兵 陈珏 钱杰 乔树宾 杨跃进 高润霖 《South China Journal of Cardiology》 CAS 2013年第3期204-210,共7页
Durable polymers used for first-generation drug-eluting stents potentially contribute to persistent inflammation and late stent thrombosis. BICARE (Lepu Medical Technology Co., Ltd, Beijing, China) is a novel polyme... Durable polymers used for first-generation drug-eluting stents potentially contribute to persistent inflammation and late stent thrombosis. BICARE (Lepu Medical Technology Co., Ltd, Beijing, China) is a novel polymer-free stent system with nanotechnology and elutes rapamycin (1.6 μg/mm2) and probucol (0.8 μg/mm2). The millpores on the surface of the stents were produced by nanotechnology. Studies on in-vitro release profile and the preliminary feasibility and safety of the BICARE stent were conducted. The results of release profile study demonstrated the ability of dual-drug polymer-free loading stents to release rapamycin and probucol in a controlled and sustained manner. The preliminary feasibility and safety of BICARE dual-drug polymer-free stent are demonstrated firstly in human study. Optical coherence tomography (OCT) findings indicated excellent stent strut coverage at 4-month. Further pivotal randomized trial will confirm if this early results could translate into longer term safety and efficacy benefits. 展开更多
关键词 NANOTECHNOLOGY drug eluting stents polymer-free human trial
原文传递
Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients
9
作者 De-Wei Wu Meng-Yue Yu +4 位作者 Hai-Yang Gao Li Zhang Fei Song Xin-Yue Zhang Yong-Jian Wu 《Chronic Diseases and Translational Medicine》 2015年第4期-,共10页
Background:Permanent polymer drug eluting stents (PP-DES) may induce inflammation of the vessel wall due to the existence of the polymer,which may delay intimal healing.Polymer-free DES (PF-DES) that eliminate the pol... Background:Permanent polymer drug eluting stents (PP-DES) may induce inflammation of the vessel wall due to the existence of the polymer,which may delay intimal healing.Polymer-free DES (PF-DES) that eliminate the polymeric carrier may potentially lead to safer DES.However,the safety and efficacy of PF-DES remains controversial.Methods:Randomized controlled trials comparing PF-DES with PP-DES were searched in online database including MEDLINE,Excerpta Medica Database (EMBASE) and Cochrane Library.Studies reporting late lumen loss (LLL),all-cause death,myocardial infarction (MI),target lesion revascularization (TLR) and late stent thrombosis (LST) were enrolled and quantitatively analyzed.Results:Ten studies enrolling 6575 patients were included in this meta-analysis.The PF-DES showed a benefit in reducing all-cause death (OR =0.77,95% CI:0.61 to 0.98,P =0.03) and long-term LLL (weighted mean difference (WMD)-0.16 mm,95% CI:-0.22 to -0.11 mm,P < 0.001),while no superiority was found in reducing short-term LLL (WMD 0.03 mm,95% CI:-0.07-0.13 mm,P =0.57),MI (OR =1.12,95% CI:0.19 to 23.18,P=0.39),TLR (OR =1.19,95% CI:0.42 to 3.38,P=0.83)and LST (OR =0.92,95%CI:0.05 to 5.71,P =0.74).Conclusion:PF-DES showed benefits in reducing long-term LLL and mortality compared with PP-DES,but no superiority was found in short-term LLL,MI,TLR and LST.These findings provide a sound basis for the wide application of PF-DES in the future. 展开更多
关键词 Drug eluting stent polymer-free DES META-ANALYSIS
原文传递
无载体含药物洗脱支架研究进展
10
作者 陆鑫 张华 《心血管病学进展》 CAS 2019年第7期1032-1034,共3页
近年来,经皮冠脉介入术已成为冠心病血运重建的主要方法。药物洗脱支架的诞生,为解决支架植入后的再狭窄带来了新希望。现简要综述新一代药物洗脱支架——无载体药物洗脱支架的临床应用。
关键词 经皮冠脉介入术 无载体 药物洗脱支架
下载PDF
无载体含药物洗脱支架治疗冠状动脉狭窄的临床疗效 被引量:4
11
作者 陈新军 郑若龙 +4 位作者 黄凤娇 杨增芯 徐卓文 李伟章 张华 《实用医学杂志》 CAS 北大核心 2018年第12期2042-2045,共4页
目的探讨国产血管内无载体含药物洗脱支架(Nano支架)治疗不稳定型心绞痛患者的安全性及有效性。方法选取在我院住院的不稳定型心绞痛患者,分为两组,比较术后12个月心血管事件、靶血管最小内膜腔面积、最小支架截面积及内膜增生面积。结... 目的探讨国产血管内无载体含药物洗脱支架(Nano支架)治疗不稳定型心绞痛患者的安全性及有效性。方法选取在我院住院的不稳定型心绞痛患者,分为两组,比较术后12个月心血管事件、靶血管最小内膜腔面积、最小支架截面积及内膜增生面积。结果随访12个月,组1心血管事件7例,组2心血管事件6例,两组差异无统计学意义(P=0.727);术后12个月,组1共有4例患者因冠状动脉严重狭窄再次行支架植入术,组2共有3例再次行支架植入术,两组差异无统计学意义(P=0.672);术后12个月,两组靶血管内膜均有增生,差异无统计学意义(P=0.985);术后12个月两组患者靶血管最小内膜腔面积差异无统计学意义(P=0.921);两组患者最小支架截面积差异无统计学意义(P=0.934)。结论 Nano支架治疗不稳定型心绞痛患者临床疗和Endeavor Resolute支架相当,心血管事件较少、临床应用安全可靠。 展开更多
关键词 冠状动脉狭窄 无载体含药物洗脱支架 Nano支架 endeavor resolute支架 血管内超声
下载PDF
Nano无载体药物支架对血清炎症因子的影响 被引量:4
12
作者 成永霞 邵芳 周庆国 《中华临床医师杂志(电子版)》 CAS 2015年第15期40-43,共4页
目的观察国产Nano无载体药物支架对血清炎症因子的影响,并探讨其对减少主要不良心脏事件的作用。方法选择2012年1月至2013年10月我院拟行经皮冠状动脉介入治疗(PCI)术的冠心病患者59例随机分为Partner组和Nano组,分别用ELISA法检测术前... 目的观察国产Nano无载体药物支架对血清炎症因子的影响,并探讨其对减少主要不良心脏事件的作用。方法选择2012年1月至2013年10月我院拟行经皮冠状动脉介入治疗(PCI)术的冠心病患者59例随机分为Partner组和Nano组,分别用ELISA法检测术前、术后24 h、1个月、3个月、6个月及12个月血清炎症因子高敏C反应蛋白(hs CRP)、白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9);术后1、3、6、10、12个月门诊或电话随访,观察有无主要不良心脏事件。结果 25例患者成功置入Partner药物支架,34例置入Nano无载体药物支架。Partner组和Nano组术前基本情况无明显差异,术后24 h hs CRP、IL-6、MMP-9均达到最高值;术前、术后24 h、术后1、3个月两组间hs CRP、IL-6、MMP-9无明显差异(P>0.05);术后6个月Partner组IL-6、MMP-9明显高于Nano组(P<0.05),但两组间hs CRP无明显差异(P>0.05);术后12个月Partner组炎症因子hs CRP、IL-6、MMP-9均明显高于Nano组(P均<0.05)。随访期间Partner组发生主要不良心脏事件明显高于Nano组(P<0.05)。结论 Nano组较Partner组炎症反应更低,进一步减少支架置入术后主要不良心脏事件,考虑与去除载体有关。 展开更多
关键词 Nano无载体药物支架 Partner药物支架 炎症因子 主要不良心脏事件
原文传递
埕海一区人工岛丛式井钻井液技术 被引量:1
13
作者 王鲁坤 黄达全 +5 位作者 王伟忠 陶瑞东 明洪涛 谢新荣 穆剑雷 陈彩凤 《钻井液与完井液》 CAS 北大核心 2008年第4期53-55,共3页
埕海一号人工岛主要开发庄海4X1和庄海8断块,是海油陆采工程的重点项目。已完成22口丛式井,根据不同地层特性选择了不同的钻井液体系,并在钻进过程中精心维护。海水聚合物钻井液的低固相、低黏度和低切力特性有效解决了明化镇组泥岩堵... 埕海一号人工岛主要开发庄海4X1和庄海8断块,是海油陆采工程的重点项目。已完成22口丛式井,根据不同地层特性选择了不同的钻井液体系,并在钻进过程中精心维护。海水聚合物钻井液的低固相、低黏度和低切力特性有效解决了明化镇组泥岩堵导管、黏附井壁、缩径等难题。新型盐水聚合物钻井液较好地解决了沙河街泥页岩坍塌、大位移定向井井眼净化、钻井液润滑性及油气层保护等难题,保证了钻井的安全施工。但当固相含量增加或提高密度后钻井液润滑性能明显降低,因此需要对体系进一步完善。筛管完成井三开使用无固相钻井完井液,取得了较好的油气层保护效果。 展开更多
关键词 定向井 钻井液配方 海水钻井液 盐水聚合物 无固相钻井液 埕海一区 滩涂钻井
下载PDF
活性自由基聚合法合成偶氮聚合物研究进展 被引量:1
14
作者 张源源 周秀华 《化工时刊》 CAS 2008年第6期62-67,共6页
偶氮聚合物具有的光致顺反异构和光学各向异性使之在光电信息技术领域具有重要的潜在应用前景。利用活性自由基聚合的方法可以在温和的条件下合成到特定结构与预定相对分子质量的偶氮聚合物,本文综述了该技术领域的最新研究进展,并对近... 偶氮聚合物具有的光致顺反异构和光学各向异性使之在光电信息技术领域具有重要的潜在应用前景。利用活性自由基聚合的方法可以在温和的条件下合成到特定结构与预定相对分子质量的偶氮聚合物,本文综述了该技术领域的最新研究进展,并对近年来出现的聚合体系与方法作了简要的评述。 展开更多
关键词 偶氮聚合物 活性自由基聚合 氮氧稳定自由基聚合(NMP) 原子转移自由基聚合(ATRP) 可逆加成-断裂链转移(RAFT)
下载PDF
无聚合物压裂液作用原理及性能影响因素概述
15
作者 魏新宇 刘建民 关富佳 《新疆石油学院学报》 2003年第4期48-51,共4页
目前 ,国内油井进行压裂施工大部分使用是含聚合物压裂液体系。但含聚压裂液不易破胶 ,返排不彻底 ,会对地层造成二次伤害 ,就此国外首先研制了无聚合物压裂液。对无聚合物压裂液易破胶、易返排 ,低伤害等优越性能和现场应用效果做了详... 目前 ,国内油井进行压裂施工大部分使用是含聚合物压裂液体系。但含聚压裂液不易破胶 ,返排不彻底 ,会对地层造成二次伤害 ,就此国外首先研制了无聚合物压裂液。对无聚合物压裂液易破胶、易返排 ,低伤害等优越性能和现场应用效果做了详细的阐述 。 展开更多
关键词 无聚合物压裂液 压裂 伤害
下载PDF
永久、可降解、无聚合物涂层支架在冠状动脉无保护左主干病变介入治疗中的临床分析 被引量:7
16
作者 周登禄 陈剑飞 +4 位作者 宋明宝 晋军 宋耀明 黄岚 赵晓辉 《第三军医大学学报》 CAS CSCD 北大核心 2019年第5期490-496,共7页
目的比较永久、可降解及无聚合物涂层3种支架治疗无保护左主干病变的安全性及有效性。方法本研究纳入了2013年1月-2017年6月于陆军军医大学(第三军医大学)第二附属医院心血管内科经冠状动脉造影诊断为冠状动脉无保护左主干病变,并行支... 目的比较永久、可降解及无聚合物涂层3种支架治疗无保护左主干病变的安全性及有效性。方法本研究纳入了2013年1月-2017年6月于陆军军医大学(第三军医大学)第二附属医院心血管内科经冠状动脉造影诊断为冠状动脉无保护左主干病变,并行支架植入术的患者共259例,按照左主干植入支架的不同分为永久性聚合物涂层支架组(PP-DES,n=153)、可降解聚合物涂层支架组(BP-DES,n=54)和无聚合物涂层支架组(PF-DES,n=52),随访至术后12个月,比较3组患者支架植入术后12个月内靶血管失败(心源性死亡、靶血管相关性心肌梗死、靶血管再次血运重建)和主要心血管不良事件(心源性死亡、非致死性心肌梗死、再次血运重建)的发生情况。结果 3组患者在性别、年龄、临床诊断、合并高危因素及病变类型、支架术式、真性分叉病变比例等方面的差异无统计学意义(P>0.05),术后12个月内靶血管失败(P=0.596)及主要心血管不良事件发生率差异无统计学意义(P=0.210)。多因素COX回归分析显示:支架类型与患者术后12个月内发生靶血管失败及主要心血管不良事件无显著相关性(P>0.05)。结论可降解聚合物涂层支架、无聚合物涂层支架治疗无保护左主干病变的靶血管失败及主要心血管不良事件发生率与永久性聚合物涂层支架相当,这两种新型支架治疗无保护左主干病变安全有效。 展开更多
关键词 冠状动脉粥样硬化性心脏病 无保护左主干病变 药物洗脱支架 永久性聚合物涂层 可降解聚合物涂层 无聚合物涂层
下载PDF
无铬鞣技术离规模化推广到底还有多远 被引量:16
17
作者 兰云军 刘建国 +2 位作者 周建飞 银德海 许晓红 《中国皮革》 CAS 北大核心 2008年第1期38-41,共4页
简要介绍了铬对环境、人类、农作物和动物的危害,分析了几种常见非铬类金属鞣剂的特点,指出金属(无铬)复合鞣剂的鞣制技术,将是无铬鞣技术重要的发展方向之一,并有可能在较短时间内获得规模化推广。
关键词 无铬鞣剂 多金属(无铬)复合鞣剂 专用助剂 制革
下载PDF
无铬鞣技术规模化推广应用的可行性 被引量:13
18
作者 兰云军 刘建国 +2 位作者 周建飞 银德海 邹祥龙 《中国皮革》 CAS 北大核心 2008年第13期44-46,54,共4页
探讨了无铬鞣制技术提出的背景,分析了非铬类主要金属鞣剂的资源情况、对环境因素构成的影响,讨论了金属(无铬)复合鞣剂鞣制技术的经济性和LTA型金属(无铬)复合鞣剂鞣革的特点与技术成熟度,从多方面论证了LTA型金属(无铬)复合鞣剂鞣制... 探讨了无铬鞣制技术提出的背景,分析了非铬类主要金属鞣剂的资源情况、对环境因素构成的影响,讨论了金属(无铬)复合鞣剂鞣制技术的经济性和LTA型金属(无铬)复合鞣剂鞣革的特点与技术成熟度,从多方面论证了LTA型金属(无铬)复合鞣剂鞣制技术的规模化推广应用是可行的。 展开更多
关键词 无铬鞣制技术 金属(无铬)复合鞣剂 规模化推广 可行性分析
下载PDF
自由基清除剂作聚合物电压稳定剂的实验研究 被引量:9
19
作者 尹毅 屠德民 +1 位作者 王新生 李忠华 《高电压技术》 EI CAS CSCD 北大核心 1999年第4期18-20,共3页
研究了温度和自由基清除剂的含量与聚乙烯试样的电树枝起始电压的关系,聚丙烯薄膜的电老化过程中,在双对数坐标下,自由基粒子数密度n和击穿强度分别随老化时间线性增加和减小。n可作为评定聚合物电老化和最终破坏的一个重要参数。自... 研究了温度和自由基清除剂的含量与聚乙烯试样的电树枝起始电压的关系,聚丙烯薄膜的电老化过程中,在双对数坐标下,自由基粒子数密度n和击穿强度分别随老化时间线性增加和减小。n可作为评定聚合物电老化和最终破坏的一个重要参数。自由基清除剂能有效地提高聚乙烯的高温电树枝起始电压。 展开更多
关键词 聚合物 自由基清除剂 电老化 电压稳定剂 聚乙烯
下载PDF
微细发泡注塑成型成核理论模型 被引量:6
20
作者 赵冬晓 胡广洪 王兆远 《塑料》 CAS CSCD 北大核心 2009年第1期104-106,40,共4页
利用经典成核理论模型对微细发泡注塑成型的成核机理进行了深入的分析,总结了经典成核理论与实际成核过程存在的差异。主要考虑了聚合物成核前后自由能的改变,对经典成核理论模型进行修正,并将改进的成核理论模型应用于PS/N2发泡模型中... 利用经典成核理论模型对微细发泡注塑成型的成核机理进行了深入的分析,总结了经典成核理论与实际成核过程存在的差异。主要考虑了聚合物成核前后自由能的改变,对经典成核理论模型进行修正,并将改进的成核理论模型应用于PS/N2发泡模型中,结果表明:修正的成核理论模型能够很好地描述聚苯乙烯的成核过程。 展开更多
关键词 微细发泡 经典成核理论 模型修正 聚合物自由能 聚苯乙烯
下载PDF
上一页 1 2 下一页 到第
使用帮助 返回顶部